![Neil Kumar](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Neil Kumar
Directeur Général chez
EIDOS THERAPEUTICS, INC.
Fortune : 336 M $ au 31/05/2026
Profil
Fondateur de BridgeBio Pharma, Inc. et de BridgeBio Pharma LLC, Neil Kumar occupe le poste de directeur général et de directeur chez BridgeBio Pharma, Inc. et de directeur général et de directeur chez BridgeBio Pharma LLC et de directeur général chez Eidos Therapeutics, Inc. (toutes deux sont des filiales de BridgeBio Pharma, Inc.). Neil Kumar est également membre du conseil d'administration de PellePharm, Inc, Navire Pharma, Inc et LianBio. Auparavant, Neil Kumar était directeur associé chez McKinsey & Co, Inc, directeur chez Third Rock Ventures LLC et vice-président du développement commercial de MyoKardia, Inc. Il a obtenu un diplôme de premier cycle et un diplôme d'études supérieures de l'université de Stanford et un doctorat du Massachusetts Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/06/2026 | 5 077 460 ( 2,59% ) | 336 M $ | 31/05/2026 | |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases -.--% | 27/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
LIANBIO -.--% | 10/04/2023 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Neil Kumar
| Sociétés | Poste | Début |
|---|---|---|
| LIANBIO | Directeur/Membre du Conseil | 01/10/2019 |
| EIDOS THERAPEUTICS, INC. | Directeur Général | 01/03/2016 |
| BRIDGEBIO PHARMA, INC. | Fondateur | 01/01/2015 |
BridgeBio Pharma LLC
 BridgeBio Pharma LLC BiotechnologyHealth Technology Discovers and develops medicines for patients with genetic diseases | Fondateur | 01/01/2015 |
BridgeBio Chemistry, Inc. | President | - |
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | President | - |
Phoenix Tissue Repair, Inc.
 Phoenix Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | President | - |
Calcilytix Therapeutics, Inc. | President | - |
Adrenas Therapeutics, Inc. | Treasurer | - |
| ░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
Anciens postes connus de Neil Kumar
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Neil Kumar
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
83
Relations au 1er degré
19
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 19 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of cardiovascular diseases | Health Technology |
PellePharm, Inc.
 PellePharm, Inc. BiotechnologyHealth Technology Develops biotechnologies to cure dermatological diseases | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of the healthcare sector. It provides financing for early stage capital requirements. It acts as a lead investor. | Finance |
BridgeBio Pharma LLC
BridgeBio Pharma LLC BiotechnologyHealth Technology Discovers and develops medicines for patients with genetic diseases | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Phoenix Tissue Repair, Inc.
Phoenix Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Navire Pharma, Inc.
 Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Adrenas Therapeutics, Inc. | |
BridgeBio Services, Inc. | |
Calcilytix Therapeutics, Inc. | |
LianBio
 LianBio BiotechnologyHealth Technology Operates as a biotechnology company focused on bringing paradigm-shifting medicines to patients | Health Technology |
BridgeBio Chemistry, Inc. |
